Dividend amount and dividend per share are quoted in the currency of the stock selected. Please note that past performance is not a reliable indicator of future returns. Important Information Please ...

Revenue: US$3.13b (up 8.8% from FY 2023). Net income: US$359.0m (up 89% from FY 2023). Profit margin: 12% (up from 6.6% in FY 2023). The increase in margin was driven by higher revenue. EPS: US$1. ...

Revenue: US$3.13b (up 8.8% from FY 2023). Net income: US$359.0m (up 89% from FY 2023). Profit margin: 12% (up from 6.6% in FY 2023). The increase in margin was driven by higher revenue. EPS: US$1.62 ...

Amman, Jordan: Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, today reports its audited results for the year ended 31 December 2024. The Group reported revenue growth of 9% (9% ...

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on Hikma Pharmaceuticals (HIK – Research Report), with a price target of p2,600.00. The company’s shares ...

RBC Capital analyst Alistair Campbell reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) today and set a price target of p2,525.00. The company’s shares closed yesterday ...

Investing.com -- Shares of Hikma Pharmaceuticals (LON:HIK) fell over 5% on Wednesday following its FY24 results, as core operating profits and weaker-than-expected margins failed to meet investor ...

"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut ...

The margin also softened, to 22.8% from 24.6% in 2023. As at 0830 GMT, shares in Hikma were down 8% at 2,122p. Riad Mishlawi, chief executive, insisted it had been "another strong year" for the ...

Investing.com -- Shares of Hikma Pharmaceuticals (LON:HIK) fell over 5% on Wednesday following its FY24 results, as core operating profits and weaker-than-expected margins failed to meet investor ...

Hikma Pharmaceuticals PLC posted 'robust' financial results for 2024, with revenue climbing 9 per cent to $3.127 billion (JT file) AMMAN — Hikma Pharmaceuticals PLC posted 'robust' financial results ...

Group core revenue up 10%, including contribution from Xellia acquisition (9% organic). Reported Group revenue up 9% Core revenue up in all three business segments – Injectables up 10%, Branded up 8% ...